Immunovia will hold a Q3 report telephone conference on Monday Nov 13th
The telephone conference is expected to last one hour and will be held in English. After a company presentation by Immunovia CEO Mats Grahn it will be possible to ask questions. Please call in a few minutes prior to the start of the telephone conference.
Date: November 13 2017
Time: 16:00 (CET)
SE: +46 8 56642662
CH: +41 225675548
DE: +49 69222229046
DK: +45 35445575
UK: +44 2030089803
US: +1 855 8315946
There will be an MP3-file available at Immunovia’s webpage under Investors/Financial reports ((http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
The Q3 results were published 8:30 (CET) November 10, 2017.
For questions or interview bookings:
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.